FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3182752918> ?p ?o ?g. }

• W3182752918 endingPage "1237" @default.
• W3182752918 startingPage "1226" @default.
• W3182752918 abstract "Cancer exerts a huge strain on the health system. The emerging resistance to the current chemotherapies demands the continuous development of new anticancer agents with lower cost, higher efficacy, and greater specificity.This study aimed at developing selective small molecules as targeted anticancer agents.The behavior of benzoxazinone 2 towards nitrogen nucleophiles, such as hydrazine hydrate, formamide, ethanolamine, aromatic amines, and thiosemicarbazide, was described. The behavior of the amino quinazolinone 3 towards carbon electrophiles and P2S5 was also investigated. The antiproliferative activity of 17 new benzoxazinone derivatives was examined against the growth of three human cancer cell lines; liver HepG2, breast MCF-7, and colon HCT-29, in addition to the normal human fibroblasts WI-38, and the selectivity index was calculated. The possible molecular pathways, such as the cell cycle and apoptosis, were investigated.Derivatives 3, 7, 8, 10, 13, and 15 had a significant (less than 10 μM) antiproliferative activity against the three cancer cell lines investigated. Derivative 7 showed the best antiproliferative profile comparable to that of doxorubicin. The selectivity index for all the effective derivatives ranged from ~5-12 folds, indicating high selectivity against the cancer cells. Derivative 15 caused ~ 7-fold and 8-fold inductions in the expression of p53 and caspase3, respectively. It also caused a ~ 60% reduction in the expression of both topoisomerase II (topoII) and cyclin-dependent kinase 1 (cdk1). Derivatives 3, 7, and 8 had a similar profile; ~ 6-8-fold increased in the expression of p53 and caspase3 but these compounds were devoid of any significant effect on the expression of topoII and cdk1. Derivatives 10 and 13 were also similar and resulted in a ~6-fold elevation in the expression ofcaspase3, and more than 60% downregulation in the expression of topoII. The results of the gene expression of topoII and caspase3 were confirmed by the measurement of the topoII concentration and caspase3 activity in the HepG2 cells.Six derivatives exerted their antiproliferative activity by arresting the cell cycle (decreasing cdk1), preventing the DNA duplication (downregulating topo II), and inducing apoptosis (inducing p53 and caspase3). One common feature in all the six active derivatives is the presence of a free amino group. These compounds have merit for further investigations." @default.
• W3182752918 created "2021-07-19" @default.
• W3182752918 creator A5004452545 @default.
• W3182752918 creator A5006945103 @default.
• W3182752918 creator A5050186251 @default.
• W3182752918 date "2022-04-01" @default.
• W3182752918 modified "2023-09-27" @default.
• W3182752918 title "Synthesis, Antiproliferative Activity, and Apoptotic Profile of New Derivatives from the Meta Stable Benzoxazinone Scaffold" @default.
• W3182752918 cites W1789332736 @default.
• W3182752918 cites W185074351 @default.
• W3182752918 cites W1969825737 @default.
• W3182752918 cites W1974903851 @default.
• W3182752918 cites W1988125845 @default.
• W3182752918 cites W2007545120 @default.
• W3182752918 cites W2014946189 @default.
• W3182752918 cites W2022162212 @default.
• W3182752918 cites W2024254896 @default.
• W3182752918 cites W2035835337 @default.
• W3182752918 cites W2041051519 @default.
• W3182752918 cites W2064495417 @default.
• W3182752918 cites W2107277218 @default.
• W3182752918 cites W2109689528 @default.
• W3182752918 cites W2174332694 @default.
• W3182752918 cites W2408988771 @default.
• W3182752918 cites W2435507289 @default.
• W3182752918 cites W2529150232 @default.
• W3182752918 cites W2547830076 @default.
• W3182752918 cites W2559215814 @default.
• W3182752918 cites W2753374156 @default.
• W3182752918 cites W2755389818 @default.
• W3182752918 cites W2795838458 @default.
• W3182752918 cites W2802770739 @default.
• W3182752918 cites W2889505391 @default.
• W3182752918 cites W2889646458 @default.
• W3182752918 cites W2893473306 @default.
• W3182752918 cites W2912038376 @default.
• W3182752918 cites W2916135772 @default.
• W3182752918 cites W2917994768 @default.
• W3182752918 cites W2952668054 @default.
• W3182752918 cites W2970111480 @default.
• W3182752918 cites W2980743803 @default.
• W3182752918 cites W2991776000 @default.
• W3182752918 cites W2996573845 @default.
• W3182752918 cites W3001356249 @default.
• W3182752918 cites W3004299012 @default.
• W3182752918 cites W3048893693 @default.
• W3182752918 cites W3093342182 @default.
• W3182752918 cites W3104293910 @default.
• W3182752918 cites W3107125928 @default.
• W3182752918 doi "https://doi.org/10.2174/1871520621666210706152632" @default.
• W3182752918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34229594" @default.
• W3182752918 hasPublicationYear "2022" @default.
• W3182752918 type Work @default.
• W3182752918 sameAs 3182752918 @default.
• W3182752918 citedByCount "1" @default.
• W3182752918 countsByYear W31827529182023 @default.
• W3182752918 crossrefType "journal-article" @default.
• W3182752918 hasAuthorship W3182752918A5004452545 @default.
• W3182752918 hasAuthorship W3182752918A5006945103 @default.
• W3182752918 hasAuthorship W3182752918A5050186251 @default.
• W3182752918 hasConcept C121608353 @default.
• W3182752918 hasConcept C147897179 @default.
• W3182752918 hasConcept C181199279 @default.
• W3182752918 hasConcept C185592680 @default.
• W3182752918 hasConcept C190283241 @default.
• W3182752918 hasConcept C2779707156 @default.
• W3182752918 hasConcept C54355233 @default.
• W3182752918 hasConcept C55493867 @default.
• W3182752918 hasConcept C62112901 @default.
• W3182752918 hasConcept C86803240 @default.
• W3182752918 hasConcept C96232424 @default.
• W3182752918 hasConcept C98274493 @default.
• W3182752918 hasConceptScore W3182752918C121608353 @default.
• W3182752918 hasConceptScore W3182752918C147897179 @default.
• W3182752918 hasConceptScore W3182752918C181199279 @default.
• W3182752918 hasConceptScore W3182752918C185592680 @default.
• W3182752918 hasConceptScore W3182752918C190283241 @default.
• W3182752918 hasConceptScore W3182752918C2779707156 @default.
• W3182752918 hasConceptScore W3182752918C54355233 @default.
• W3182752918 hasConceptScore W3182752918C55493867 @default.
• W3182752918 hasConceptScore W3182752918C62112901 @default.
• W3182752918 hasConceptScore W3182752918C86803240 @default.
• W3182752918 hasConceptScore W3182752918C96232424 @default.
• W3182752918 hasConceptScore W3182752918C98274493 @default.
• W3182752918 hasIssue "6" @default.
• W3182752918 hasLocation W31827529181 @default.
• W3182752918 hasLocation W31827529182 @default.
• W3182752918 hasOpenAccess W3182752918 @default.
• W3182752918 hasPrimaryLocation W31827529181 @default.
• W3182752918 hasRelatedWork W1992826282 @default.
• W3182752918 hasRelatedWork W2005490888 @default.
• W3182752918 hasRelatedWork W2351136637 @default.
• W3182752918 hasRelatedWork W2358789216 @default.
• W3182752918 hasRelatedWork W2366035116 @default.
• W3182752918 hasRelatedWork W2376744432 @default.
• W3182752918 hasRelatedWork W2382976440 @default.
• W3182752918 hasRelatedWork W2389323732 @default.
• W3182752918 hasRelatedWork W2389705313 @default.

• next